Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation
Open Access
- 1 January 2010
- journal article
- research article
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 17 (1) , 88
Abstract
Effective vaccination against human papillomavirus (HPV) represents an opportunity to control cervical cancer. Peptide-based vaccines targeting HPV E6 and/or E7 antigens while safe, will most likely require additional strategies to enhance the vaccine potency. We tested the HPV-16 E7 peptide-based vaccine in combination with a strategy to enhance CD4+ T help using a Pan HLA-DR epitope (PADRE) peptide and a strategy to enhance dendritic cell activation using the toll-like receptor 3 ligand, poly(I:C). We observed that mice vaccinated with E7 peptide-based vaccine in combination with PADRE peptide and poly(I:C) generated better E7-specific CD8+ T cell immune responses as well as significantly improved therapeutic anti-tumor effects against TC-1 tumors compared to E7 peptide-based vaccine with either PADRE peptide or poly(I:C) alone. Furthermore, we found that intratumoral vaccination with the E7 peptide in conjunction with PADRE peptide and poly(I:C) generates a significantly higher frequency of E7-specific CD8+ T cells as well as better survival compared to subcutaneous vaccination with the same regimen in treated mice. The combination of PADRE peptide and poly(I:C) with antigenic peptide is capable of generating potent antigen-specific CD8+ T cell immune responses and antitumor effects in vaccinated mice. Our study has significant clinical implications for peptide-based vaccination.Keywords
This publication has 27 references indexed in Scilit:
- Preventive and therapeutic HPV vaccines2007
- Opportunities to improve the prevention and treatment of cervical cancer.Current Molecular Medicine, 2007
- Natural History of Human Papillomavirus Type 16 Virus-Like Particle Antibodies in Young WomenCancer Epidemiology, Biomarkers & Prevention, 2004
- Papillomaviruses and cancer: from basic studies to clinical applicationNature Reviews Cancer, 2002
- The causal relation between human papillomavirus and cervical cancerJournal of Clinical Pathology, 2002
- Persistent human papillomavirus infection and cervical neoplasiaThe Lancet Oncology, 2002
- Natural T-helper immunity against human papillomavirus type 16 (hpv16) e7-derived peptide epitopes in patients with hpv16-positive cervical lesions: Identification of 3 human leukocyte antigen class ii-restricted epitopesInternational Journal of Cancer, 2001
- Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7.2001
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999
- Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cellsEuropean Journal of Immunology, 1993